- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | Tela Bio Launches OviTex IHR In U.S. | 1 | RTTNews | ||
| 15.04. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.04. | TELA Bio, Inc.: TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR - Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures | 1 | GlobeNewswire (USA) | ||
| 08.04. | TELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy | 103 | GlobeNewswire (Europe) | MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,... ► Artikel lesen | |
| 22.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.03. | TELA Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.03. | TELA Bio Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 21.03. | Recap: TELA Bio Q4 Earnings | 1 | Benzinga.com | ||
| 21.03. | TELA Bio, Inc.: TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results | 82 | GlobeNewswire (Europe) | MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that... ► Artikel lesen | |
| 21.03. | TELA Bio launches FDA-approved hernia mesh fixation devices | 1 | Investing.com | ||
| 21.03. | TELA Bio launches Liquifix surgical devices in the U.S. | 1 | Seeking Alpha | ||
| 21.03. | Tela Bio Announces Commercial Launch Of Liquifix Devices In U.S. | - | RTTNews | ||
| 21.03. | TELA Bio, Inc.: TELA Bio Announces U.S. Commercial Launch of LIQUIFIX - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery | 95 | GlobeNewswire (Europe) | MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,... ► Artikel lesen | |
| 20.03. | Preview: TELA Bio's Earnings | 2 | Benzinga.com | ||
| 20.03. | TELA Bio Announces Sale Of Distribution Rights Related To NIVIS Fibrillar Collagen Pack | - | RTTNews | ||
| 20.03. | TELA Bio divests NIVIS rights to MiMedx for up to $12 million | 1 | Investing.com | ||
| 20.03. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.02. | TELA Bio, Inc.: TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results | 1 | GlobeNewswire (USA) | ||
| 23.02. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 222 | GlobeNewswire (Europe) | MALVERN, Pa., Feb. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 19.01. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 192 | GlobeNewswire (Europe) | MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -3,11 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,085 | +1,40 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,862 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,710 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,080 | +0,93 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| RECURSION PHARMACEUTICALS | 8,790 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ARCTURUS THERAPEUTICS | 26,520 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 1,010 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 9,430 | 0,00 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,030 | 0,00 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,195 | 0,00 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,460 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,590 | 0,00 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,920 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
TELA BIO INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,640 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
